Clinical trials: Tauopathies
Alzheimer's Disease
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
This is a multi-center, randomized, double-blind placebo-controlled safety study conducted in 2 study cohorts. In Cohort 1, subjects with Alzheimer's disease (n=250) will receive Dimebon 20 mg or placebo TID for 26 weeks.
- Trial name
- NCT00838110
- Testing
- Dimebon
- Where
- 118 sites in United States, Canada and 1 more
- Volunteers
- 742 people
- Sponsor
- Pfizer
Alzheimer Disease
Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects
Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of [C14] CT1812
- Trial name
- COG0108 (NCT05225389)
- Testing
- 300 mg [C14] CT1812
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cognition Therapeutics
Alzheimer Disease, Psychotic Disorders
Antipsychotic Discontinuation in Alzheimer's Disease
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established.
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Trial name
- ADAD (NCT00417482)
- Testing
- risperidone
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- New York State Psychiatric Institute
Early Alzheimer's Disease
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype.
- Trial name
- APOLLOE4 (NCT04770220)
- Testing
- Experimental: ALZ-801
- Where
- 95 sites in United States, Canada and 7 more
- Volunteers
- 325 people
- Sponsor
- Alzheon Inc.
Alzheimer Disease
Phase IIa L-serine Trial for eAD
This is a Phase IIa, randomized, double-blind, placebo controlled trial. Subjects for participation in this study will be identified by the Investigator based on their Clinical Dementia Rating score which will be completed as…
- Trial name
- LSPI-2 (NCT03062449)
- Testing
- L-Serine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Aleksandra Stark
Polypharmacy, Alzheimer Disease and Related Dementias
Aligning Medications With What Matters Most
The Aligning Medications with What Matters Most (ALIGN) study will assess the feasibility and preliminary efficacy of a deprescribing intervention to reduce medication regimen complexity and treatment burden for people living…
- Trial name
- ALIGN (NCT04938648)
- Testing
- Pharmacist-led deprescribing intervention
- Where
- 2 sites in United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
POSTOPERATIVE DELIRIUM, POSTOPERATIVE COGNITIVE DECLINE
Daridorexant to Prevent Delirium After Heart Surgery
The goal of this phase 2 clinical trial is to demonstrate the feasibility of the current study methods and obtain preliminary data for an adequately powered trial of daridorexant with the aim of preventing delirium after heart…
- Trial name
- NCT06630390
- Testing
- Daridorexant 50 mg
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Rochester
Alzheimer's Disease
The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease
This study will examine whether the administration of galantamine is effective for improvement of attention and more effective for patients with serious disturbance of attention by administering galantamine to patients with…
- Trial name
- NCT01054976
- Testing
- Galantamine
- Volunteers
- 99 people
- Sponsor
- Janssen Korea, Ltd., Korea
Dementia, Alzheimer Disease
The Healthy Patterns Sleep Study
The Healthy Patterns Study intervention is a home-based activity intervention designed to improve symptoms of circadian rhythm disorders (CRD) and quality of life (QOL) in home-dwelling persons with dementia.
- Conditions
- Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder
- Trial name
- NCT03682185
- Testing
- Attention-Control Condition, Timed Activity Intervention
- Where
- United States
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Dementia, Alzheimer Type
Technology Intervention to Support Caregiving for Alzheimer's Disease (I-CARE)
The specific aims of this study are 1) to test the trial and intervention feasibility of Brain Care Notes (BCN) app, 2) To estimate the effect size of BCN on reducing informal caregiver burden at 6 months, and 3) To estimate the…
- Trial name
- I-CARE (NCT03119259)
- Testing
- ABC Clinical Program, BCN
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Indiana University
Alzheimer's Disease
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD.
- Trial name
- NCT03828747
- Testing
- Semorinemab, [18F]GTP1
- Where
- 49 sites in United States, France and 2 more
- Volunteers
- 272 people
- Sponsor
- Genentech, Inc.
Dementia, Alzheimer Type, Weight Loss
Partners at Meals - Respite Care and Home (PAM)
The goal of this study was to test the efficacy of a mealtime intervention in respite care centers for people with dementia and their caregivers.
- Trial name
- PAM (NCT03622814)
- Testing
- Partners at Meals, Enhanced Usual Condition
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Metabolic Syndrome, Normal Cognition
Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or Older
Background: In Alzheimer s disease (AD) the brain cannot use glucose as a fuel. The brain can use ketones as a fuel instead of glucose. Researchers want to test a supplement, Ketone Ester (KE).
- Trial name
- NCT04421014
- Testing
- Ketone Ester drink
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- National Institute on Aging (NIA)
Alzheimer's Disease
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
This study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.
- Trial name
- NCT02585934
- Testing
- RVT-101
- Where
- 197 sites in United States, Argentina and 17 more
- Volunteers
- 1,315 people
- Sponsor
- Axovant Sciences Ltd.
Cerebral Small Vessel Diseases, Stroke, Lacunar
LACunar Intervention (LACI-2) Trial-2
About 35,000 people each year in the UK have a type of stroke, called 'lacunar' or 'small vessel' stroke, which is different to other common types of stroke and for which there is no proven treatment.
- Trial name
- LACI-2 (NCT03451591)
- Testing
- Isosorbide Mononitrate XL (ISMN), Cilostazol, ISMN XL and Cilostazol
- Where
- United Kingdom
- Volunteers
- 363 people
- Sponsor
- University of Edinburgh
Alzheimer's Disease
Riluzole in Mild Alzheimer's Disease
Cognitive aging is a major source of disability in an increasingly aging population. The paucity of effective treatments for cognitive aging disorders, and most importantly in Alzheimer's disease instigates a need for further…
- Trial name
- NCT01703117
- Testing
- Riluzole
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Aging
Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD).
- Trial name
- STAMINA (NCT05422885)
- Testing
- Dasatinib, Quercetin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Lewis Lipsitz
Mild Cognitive Impairment
Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure.
- Trial name
- LATTICE (NCT03185208)
- Testing
- Lithium Carbonate
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Ariel Gildengers, MD
Alzheimer's Disease
A Study of Semagacestat for Alzheimer's Patients
The primary objective of the original study was to assess the safety of semagacestat in Alzheimer's disease (AD) patients during 24 months of open-label treatment.
- Trial name
- Identity XT (NCT01035138)
- Testing
- semagacestat
- Where
- 71 sites in United States, Australia and 12 more
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Dementia, Alzheimer Disease
Efficacy Study of Kinto Care Coaching for Dementia Family Caregivers
The goal of this clinical trial is to evaluate Kinto's Care Coaching intervention for dementia caregivers. The main questions it aims to answer are: Does the intervention help caregivers to address their general caregiving goals…
- Conditions
- Dementia, Alzheimer Disease, Lewy Body Disease, Vascular Dementia
- Trial name
- NCT05916664
- Testing
- Kinto Care Coaching
- Where
- United States
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- Kinto